Tasca Therapeutics Raises $52 Million with Co-leaders Cure and Regeneron Ventures
12/11/24, 3:34 AM
Location
Money
$52 million
Industry
biotechnology
Type
partnership
Tasca Therapeutics, a newly-minted small molecular inhibitor company, has raised $52 million in a Series A financing round. The round was co-led by Cure and Regeneron Ventures, with participation from Invus Group. The company plans to develop oncology drugs that target specific lipid-binding pockets on proteins.
Company Info
Location
349-351 newbury street
boston, massachusetts, united states
Additional Info
Tasca Therapeutics is revolutionizing drug development by unlocking the potential of post-translational protein modifications. Using state-of-the-art chemical biology, computational approaches, and targeted inhibition at key metabolic nodes, Tasca tackles previously undruggable targets. Focused on hard-to-treat oncology indications, Tasca leverages its proprietary platform to develop innovative small-molecule drugs, paving the way for breakthroughs in cancer treatment.